Trevi Therapeutics, Inc. (TRVI)
NASDAQ: TRVI · Real-Time Price · USD
7.64
-0.23 (-2.92%)
At close: Jul 28, 2025, 4:00 PM
7.60
-0.04 (-0.52%)
Pre-market: Jul 29, 2025, 6:20 AM EDT

Company Description

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough.

The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis.

Trevi Therapeutics, Inc. has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations.

The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Trevi Therapeutics, Inc.
Trevi Therapeutics logo
CountryUnited States
Founded2011
IPO DateMay 7, 2019
IndustryBiotechnology
SectorHealthcare
Employees26
CEOJennifer Good

Contact Details

Address:
195 Church Street, 16th Floor
New Haven, Connecticut 06510
United States
Phone203 304 2499
Websitetrevitherapeutics.com

Stock Details

Ticker SymbolTRVI
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$10.00
CIK Code0001563880
CUSIP Number89532M101
ISIN NumberUS89532M1018
Employer ID45-0834299
SIC Code2834

Key Executives

NamePosition
Jennifer L. GoodCo-Founder, Chief Executive Officer, President and Director
Lisa DelfiniChief Financial Officer
Dr. James V. Cassella Ph.D.Chief Development Officer
Dr. Thomas R. Sciascia M.D.Co-Founder and Chief Scientific Officer
Christopher GallettaController and Chief Accounting Officer
Katie McManusCommunications Manager
Farrell Simon Pharm.D.Chief Commercial Officer
Katherine Takaki Ph.D.Senior Vice President of Global Regulatory Affairs

Latest SEC Filings

DateTypeTitle
Jul 9, 2025SCHEDULE 13GFiling
Jun 17, 20258-KCurrent Report
Jun 4, 20258-KCurrent Report
Jun 4, 2025424B5Filing
Jun 2, 2025424B5Filing
Jun 2, 20258-KCurrent Report
Jun 2, 20258-KCurrent Report
May 15, 2025SCHEDULE 13G/AFiling
May 15, 2025SCHEDULE 13G/AFiling
May 8, 202510-QQuarterly Report